TENAX THERAPEUTICS, INC. Income Statement
TENX|7 years of annual SEC 10-K data (FY2012-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
TENAX THERAPEUTICS, INC. reported $0 in revenue and $18M in net loss for FY2025. Revenue has grown at a 11.4% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.24 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $158.9K | $158.9K | $1.2M | $363.8K | $103.2K |
| Cost of Revenue | - | - | $129.8K | $129.8K | $43.1K | $51.3K | $219.2K |
| Gross Profit | - | - | -$104.1K | -$104.1K | $49.6K | $49.3K | $103.2K |
| SG&A Expense | $6.8M | $5.0M | $13.8M | $13.8M | $3.7M | $6.1M | $7.7M |
| R&D Expense | $12.7M | $3.2M | $3.0M | $3.0M | $2.5M | $2.5M | $2.7M |
| Operating Income | -$19.5M | -$8.2M | -$16.6M | -$16.6M | -$5.2M | -$8.2M | $10.6M |
| Interest Expense | $23.0K | $24.0K | $2.2M | $2.2M | $4.2M | $7.4M | -$171.6K |
| Income Tax | $0 | $0 | $0 | $0 | - | - | - |
| Net Income | -$17.6M | -$7.7M | -$19.5M | -$19.5M | -$9.4M | -$15.7M | $10.4M |
| EPS (Basic) | -$1.15 | -$31.04 | - | - | -$6.29 | -$12.12 | -$0.45 |
| EPS (Diluted) | -$1.15 | -$31.04 | -$2.71 | -$2.71 | -$6.68 | -$14.07 | -$0.45 |
| Shares Outstanding | 3.4M | 298.3K | 28.1M | 27.9M | 1.9M | 1.5M | 23.4M |
| Gross Margin | - | - | -65.5% | -65.5% | 4.2% | 13.5% | 100.0% |
| Operating Margin | - | - | -10452.1% | -10452.1% | -435.7% | -2259.7% | 10238.4% |
| Profit Margin | - | - | -12296.2% | -12296.2% | -790.6% | -4319.2% | 10127.6% |